Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

Athersys Reports Third Quarter 2013 Results

Globe Newswire November 14, 2013

Athersys Recognized Among Fastest Growing Companies in North America on Deloitte's 2013 Technology Fast 500(TM)

Globe Newswire November 13, 2013

The Global Revolution in Biotechnology and the Impact of Regenerative Medicine

Accesswire November 7, 2013

Athersys to Host Third Quarter 2013 Financial Results Call

Globe Newswire October 24, 2013

Athersys Extends Financing Agreement with Aspire Capital to Support Further Growth and Development of Portfolio

Accesswire October 23, 2013

Athersys Enters Into $25 Million Equity Facility to Replace Expiring Agreement With Aspire Capital

Globe Newswire October 23, 2013

Athersys to Present at 2013 Stem Cell Meeting on the Mesa

Globe Newswire October 7, 2013

Third Annual Stem Cell Meeting on the Mesa Regen Med Partnering Forum Announces Presenting Companies

Marketwired August 15, 2013

Athersys Reports Second Quarter 2013 Results

Globe Newswire August 13, 2013

Athersys Receives Fast Track Grant for Development of MultiStem in Heart Attack Patients

Accesswire August 13, 2013

Athersys Announces Grant to Support Clinical Advancement of Its MultiStem(R) Regenerative Medicine Program for Heart Attack Patients

Globe Newswire August 6, 2013

Athersys to Host Second Quarter 2013 Financial Results Call

Globe Newswire July 29, 2013

MultiStem(R) Cell Therapy May Overcome Major Challenges in Organ Transplantations

Globe Newswire July 9, 2013

Regenerative Medicine Investors Eyeing Reformation of Pharmaceutical Affairs Law in Japan

Accesswire June 10, 2013

Athersys Reports First Quarter 2013 Results

Globe Newswire May 14, 2013

Athersys to Present at 12th Annual Needham Healthcare Conference

Globe Newswire April 25, 2013

Athersys to Host First Quarter 2013 Financial Results Call

Globe Newswire April 18, 2013

Analysis Reports On Active NASDAQ Stocks: (NASDAQ: ATHX), (NASDAQ: PDLI)

Accesswire April 18, 2013

Athersys Announces Authorization of Stem Cell Clinical Trial for Stroke in the United Kingdom

Globe Newswire April 17, 2013

Athersys Recognized in Peer-Reviewed Journals as Stock Maintains Strong Upward Move

Accesswire April 12, 2013